Search

everythinglearnresearchcommunity

for

Search:↓

The user experienced significant hair regrowth and reduced shedding after using finasteride, dutasteride, and topical minoxidil for six months, with no major side effects. The user emphasizes the importance of tracking progress and plans to continue the treatment indefinitely.

The conversation discusses the comparison of Pyrilutamide Phase II US trial results with 1 mg finasteride for hair loss treatment. It mentions that the total hair count increase in the US trial was not as good as the China trial.

PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.

Some users experience worsening hair loss with dutasteride, while others improve after initial shedding. Many switch back to finasteride due to better results or fewer side effects, often using minoxidil and topical treatments.

The user is experiencing increased hair loss 9 months into a treatment with topical finasteride and minoxidil, along with supplements, and is questioning if this is a temporary phase or if the treatment is ineffective. Opinions vary, with some suggesting shedding is normal, while others debate the effectiveness of topical treatments and the impact of supplements.

Verteporfin human clinical trials for hair loss may start in 2025. Additional resources and presentations are available for more information.

People with diffuse thinning and retrograde hair loss are discussing treatments like finasteride, minoxidil, and dutasteride, with some reporting improvements and others experiencing issues like scalp inflammation and increased sebum. Suggestions include addressing scalp inflammation, considering gut health, and possibly using topical antiandrogens or micro-needling.

The user has been using finasteride and dutasteride for six months, experiencing a complete stop in hair shedding but minimal regrowth. They are considering adding RU58841 for potential regrowth, with advice suggesting patience as significant results often take 12-24 months.

PP405 is a promising hair loss treatment that may outperform minoxidil and finasteride by reviving dormant follicles and promoting significant regrowth. Results from ongoing trials are awaited, with a potential market release between 2028-2030.

The conversation discusses whether to continue using finasteride or switch to dutasteride after one year, with users generally advising to stick with finasteride for more time due to positive results and potential risks of switching. Minoxidil is also being used, and some suggest considering a hair transplant for further improvement.

A 22-year-old male experienced positive hair regrowth after using oral minoxidil and finasteride for over four months, noting slight changes in hair density. He initially used topical minoxidil but switched to oral due to having pets, experiencing minimal shedding and no significant side effects after initial lethargy from finasteride.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

The conversation discusses the effectiveness of topical tretinoin as a monotherapy for hair loss, with users suggesting it may not be as effective as minoxidil or finasteride. The original poster is considering other options like a phenol peel and is concerned about the risks of derma rolling.

A user used dutasteride 0.5mg for 3 months and is unsure about hair regrowth, noting some greying. Responses suggest improvement and that full regrowth may take time with shedding cycles.

A user's plan to use Zix and topical finasteride (5AR inhibitors) for hair loss, followed by blood testing before/after. The user has suggested creating a fund to cover part of the cost of their blood tests. Replies to their post discuss the effectiveness of the treatments.

Reincarnation humorously suggested as a hair restoration method, with exaggerated and satirical discussions on finasteride use. The conversation includes jokes about side effects and the absurdity of extreme measures for hair loss.

The user experienced significant hair loss after stopping a treatment of 5% Minoxidil and 0.1% Finasteride, which they had used from December 2021 to January 2024. They resumed the treatment in April 2025, hoping for regrowth, and are considering additional treatments like transplants and steroid injections.

The user is experiencing hairline recession and plans to use minoxidil, finasteride, and biotin for a year, considering a hair transplant if needed. They seek advice on their treatment plan and additional ways to support hair growth.

The user switched from finasteride to dutasteride for stronger hair loss treatment, despite initial success with finasteride. They experienced significant shedding with dutasteride but remain hopeful for regrowth, emphasizing patience and the importance of giving treatments time to work.

The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.

Verteporfin is being explored for its potential to improve hair transplant outcomes by reducing scarring and increasing donor hair follicles. There is skepticism about the results, with some claiming misleading presentation of evidence.

The post is about a user's progress pictures of their hair loss over the course of a year. The user started taking oral finasteride and using topical Rogaine foam for better results.

The user experienced hair shedding and follicle shrinkage when using retinoic acid, despite trying different concentrations and frequencies. The hair loss persisted for six months but regrew after stopping the treatment.

The user experienced hair loss diagnosed as chronic Telogen Effluvium and male pattern baldness, treated with finasteride and minoxidil, later switching to dutasteride due to side effects but with limited success. The user plans to return to finasteride due to side effects from dutasteride, while others suggest maintaining consistent treatment and considering additional options like oral minoxidil and lifestyle changes.

A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.

After 6 years of finasteride losing effectiveness for hair loss, the user switched to dutasteride and topical minoxidil, seeing good progress after 7 months without significant side effects. They transitioned from finasteride to dutasteride over 2 months against doctor's advice.

The user is considering using CB or clascoterone for hair loss, potentially as an alternative to RU. They're also contemplating asking a dermatologist for topical clascoterone cream to apply to their temple.

The user has been using minoxidil for 3 years but started experiencing hair loss again. They began using fluridil a week ago, noticed less shedding and itching, and are considering whether to wait for fluridil results or start using finasteride as well.

The user has been using finasteride for 6 months and minoxidil for 12 months to address hair loss and recently started estradiol monotherapy for additional benefits. They are unsure if their hair is regrowing and are seeking advice on their progress.

A user experienced hair thinning after inconsistent use of finasteride and minoxidil while living abroad. They are now considering switching to dutasteride, which some believe is more effective, though others caution it may not work better for everyone.